Panellists voted by 8 to 3 – with one abstention – to change the CDC recommendations to state that MMRV is not recommended ...

In today's pharmaphorum podcast, host Jonah Comstock speaks with Alice Valder Curran, a partner at Hogan Lovells and our ...

Alzheimer’s and Parkinson’s pipelines are rapidly expanding beyond amyloid and into next-generation mechanisms such as ...

There is only one approved drug for ultra-rare disease fibrodysplasia ossificans progressiva (FOP) on the US market, but ...

UK-based electronRx will launch a digital health technology (DHT) to help patients with respiratory disease manage their ...

Novo Nordisk is also ahead in the race to bring an oral GLP-1 to market for weight loss, as it has already filed semaglutide for FDA approval, with a decision before the end of this year, while Lilly ...

The $14.50-per-share deal equates to a purchase price of $2.4 billion at closing, with Roche dangling another $6 per share in ...

The importance of AI in pharma and life sciences cannot be overstated. Regardless of the aspect of industry you examine, ...

Dr Susan Monarez told lawmakers today that Health and Human Services (HHS) Secretary Robert F Kennedy Jr said he planned to ...

In conversation with Mark Green, founder and CEO of Change Rebellion, pharmaphorum seeks practical advice for our readers who ...

In this episode of our Frontiers Health limited series of the pharmaphorum podcast, Deep Dive editor Eloise McLennan speaks ...

The data in non-diabetic subjects with obesity (a body mass index of 30 or more) reveal that patients on a 6 mg daily dose of ...